All In Biotech

Drug Trial Radar · NCT05525715

A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis

A Study of Phase Ⅰb/II to Evaluate the Safety, Efficacy and Pharmacokinetic Characteristics of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Sep 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 260 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

260

Planned (sponsor's estimate)

Start

Oct 2022

Primary completion

Dec 2025

Study completion Dec 2025

Sponsor

Sponsor type
Industry
First posted
Sep 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase Ib/II, randomized, double-blind, placebo-controlled, parallel, multicenter study of a certain phase to evaluate the efficacy, safety, and pharmacokinetic characteristics of QY201 tablet in subjects in moderate to severe atopic dermatitis

Conditions

  • Atopic Dermatitis

Interventions

  • 2mg QY201 tablets or 2mg QY201 placebo,BIDDrug

    2mg QY201 tablets or 2mg QY201 placebo,BID

  • 5mg QY201 tablets or 5mg QY201 placebo,BIDDrug

    5mg QY201 tablets or 5mg QY201 placebo,BID

  • 10mg QY201 tablets or 10mg QY201 placebo,QDDrug

    10mg QY201 tablets or 10mg QY201 placebo,QD

  • 10mg QY201 tablets or 10mg QY201 placebo,BIDDrug

    10mg QY201 tablets or 10mg QY201 placebo,BID

  • 15mg QY201 tablets or 15mg QY201 placebo,BIDDrug

    15mg QY201 tablets or 15mg QY201 placebo,BID

  • 20mg QY201 tablets or 20mg QY201 placebo,BIDDrug

    20mg QY201 tablets or 20mg QY201 placebo,BID

  • 5mg QY201 tablets,BIDDrug

    5mg QY201 tablets,BID

  • 10mg QY201 tablets,BIDDrug

    10mg QY201 tablets,BID

  • 20mg QY201 tablets,BIDDrug

    20mg QY201 tablets,BID

  • QY201 placebo,BIDDrug

    QY201placebo,BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (AEs)- Phase ⅠbTime frame: From the first administration to 28 days after the last administration of the study drug
  2. Percentage of Participants Achieving >=75% Improvement From Baseline in Eczema Area and Severity Index (EASI75) Response at Week 12- Phase ⅡTime frame: Week 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.